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Classical swine fever virus (CSFV) causes a highly con-
tagious disease among swine that has an important economic 
impact worldwide. CSFV strain LOM is an attenuated virus 
of low virulent strain of Miyagi isolated from Japan in 1956.  
Eight DNA fragments representing the genome of the CSFV 
strain LOM were obtained by RT-PCR. These were used to 
determine the complete nucleotide sequence and construct a 
full-length cDNA clone which was called Flc-LOM. Sequence 
analysis of the recombinant clone (Flc-LOM) revealed the 
presence of eight mutations, resulting in two amino acid 
substitutions,  when  compared  to  the  parental  sequence. 
RNA transcripts of both LOM and Flc-LOM were directly 
infectious in PK-15 cells. The rescued Flc-LOM virus grew 
more slowly than the parental virus, LOM, in the cells. 
Intramuscular immunization with Flc-LOM was safe and 
highly  immunogenic  in  pigs;  no  clinical  signs  or  virus 
transmission  to  sentinel  animals  were  observed  after  35 
days. CSFV-specific neutralizing antibodies were detected 
14 days post-infection. After challenge with the virulent 
CSFV strain SW03, pigs immunized with Flc-LOM were 
shown to be fully protected. Thus, our newly established 
infectious clone of CSFV, Flc-LOM, could serve as a vaccine 
candidate.
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Introduction
Classical swine fever virus (CSFV) is the etiological 
agent of classical swine fever, a devastating disease of 
swine and wild boar also known as hog cholera. This 
disease can have an acute or chronic course and causes 
significant economic losses in the pig industry worldwide 
[6]. Together with bovine viral diarrhea virus (BVDV) and 
border disease virus, CSFV belongs to the genus Pestivirus 
within the Flaviviridae family [29]. The spherical virions 
are 40∼60 nm in diameter. The genome is not segmented 
and contains a single positive-sense RNA strand about 
12.3 kb in length. The 5´ and 3´ ends of the genome do not 
have a cap or poly (A) tract [17]. CSFV proteins are 
translated from genomic RNA as a single large polyprotein 
of about 3,900 amino acids, which is co- and post- 
translationally processed by cellular and viral proteases to 
form mature viral proteins [23,33].
Two main strategies for controlling CSF, depending on 
the epidemiological conditions of the affected geographical 
area, are systematic prophylactic vaccination with a live 
attenuated vaccine and a non-vaccination, stamping-out 
policy. The former technique makes it impossible to 
distinguish naturally infected from vaccinated animals, 
and the latter carries a risk of enormous outbreaks which 
can result in huge economic losses in areas with a high 
density of pigs [7]. Although potentially serious side 
effects such as pig chromosome aberrations exist after 
vaccination with a live attenuated vaccine [9], vaccination 
has been the most effective tool for preventing CSF. For 
eradication and control purposes, available CSFV vaccines 
are based on the Chinese (C) strain, cell culture-adapted 
Japanese guinea pig exaltation-negative (GPE
򰠏) strain, or 
French cell culture-adapted Thiverval strain and its 
derivatives [28]. These vaccines, which have been proven 
to be efficacious and safe, are obtained after serial passage 
of CSFV isolates in tissue cultures or rabbits, and the 
genetic basis of their attenuation is unknown.
The LOM strain, an attenuated virus of low virulent strain 
of Miyagi isolate from Japan, has been used as a live 82    Gil-Soon Park et al.
attenuated CSF vaccine in Korea for more than 30 years 
[11]. Several studies have described the use of the 
attenuated LOM virus as a vaccine strain. This strain was 
first isolated by Sato et al. [26] in 1956 from naturally 
infected swine in the Miyagi Prefecture (Japan) and was 
further attenuated in their laboratory by continuous 
propagation in bovine kidney cells. A bovine kidney tissue 
culture-attenuated live vaccine, the LOM strain, was 
established by the National Veterinary Assay Laboratory in 
Japan in 1964 [20]. The LOM strain was cloned, attenuated, 
and then tested as vaccine candidate from 1968 to 1969 in 
the field by Istitute of Veterinary Research (IVR) in Korea 
[11,12]. The strain has been used as a live vaccine to 
eradicate CSFV in the field since 1974, and was shown to 
be safe and highly immunogenic in pigs for many decades 
[13]. 
A full-length cDNA clone that rescues infectious viral 
progeny would be an excellent tool for the functional 
characterization of viral gene products, analysis of virus 
and RNA replication, determination of virulence factors, 
and elucidation of mechanisms involved in viral patho-
genesis. Such a clone has served as an invaluable tool for 
developing a CSF marker vaccine. As with many other 
viruses, the generation and use of infectious CSFV clones 
have provided new opportunities for understanding and 
characterizing the mechanisms of viral replication and 
pathogenesis [21]. Information generated using reverse 
genetics has enabled the identification of CSFV proteins or 
protein domains that determine virulence and host range, 
as well as facilitating the rational design and development 
of new vaccines against CSF. To date, all infectious cDNA 
clones that are routinely used for molecular studies have 
been established from the moderately virulent Alfort/187 
strain of CSFV [22]; the C-strain, which is the most 
well-known and widely used attenuated vaccine strain in 
the world [19]; the highly virulent Eystrup strain; and the 
avirulent Riems/IVI vaccine strain [16].  Most of the novel 
modified CSF vaccines, including deletion mutants, 
chimeric viruses, and replicons, have been developed by 
constructing cDNA clones of CSFV and BVDV [18, 
19,22,30]. These have the potential for inducing immunity 
to an extent similar to that of conventional live attenuated 
vaccines, and present the possibility of discriminating 
vaccinated from infected animals.
The objectives of the present study were to construct a 
full-length cDNA clone of the original attenuated CSFV 
strain LOM, and to compare the characteristic features of 
the parental and recombinant (Flc-LOM) strains including 
safety, efficacy, and in vitro and  in vivo utility. An 
infectious cDNA clone of the CSFV LOM strain, Flc- 
LOM, was generated. We showed that pigs immunized 
with Flc-LOM were fully protected against CSFV infection 
when exposed to the virulent SW03 strain. Establishment 
of infectious clones derived from a live attenuated CSFV 
vaccine strain should significantly facilitate ongoing 
studies to determine the molecular basis of virulence and 
attenuation as well as enabling accurate genomic mani-
pulation. Furthermore, these can serve as valuable tools for 
developing new potent marker vaccine.
Materials and Methods 
Cells and viruses
The porcine kidney cell line PK-15 (ATCC, USA) was 
maintained in α-minimal essential medium (α-EMEM; 
Invitrogen, USA) supplemented with 10% fetal bovine 
serum (Invitrogen, USA) which has no antibody against 
BVDV at 37
oC in a humidified atmosphere of 5% CO2. The 
LOM strain (accession No. EU789580, GenBank) was 
developed as a CSFV vaccine and was distributed to five 
Korean animal vaccine companies by the Animal, Plant 
and Fisheries Quarantine and Inspection Agency, Korea.
The nucleotide sequence of Flc-LOM rescued from a 
full-length infectious clone has been submitted to GenBank 
(accession No. EU915211). The virulent CSFV strain 
SW03 was previously obtained from field isolates in Korea 
[2,31]. Virus stocks were prepared by several passages in 
PK-15 cells. Virus preparations were tested for the absence 
of BVDV, porcine circovirus-2, and mycoplasma by poly-
merase chain reaction (PCR) using specific primers against 
them. 
Recombinant DNA procedures
Escherichia coli XL-1 Blue (Stratagene, USA) was 
grown at 37
oC in Luria-Bertani medium (Becton Dickinson, 
USA) supplemented with ampicillin (100 μg/mL; Sigma, 
USA). Standard recombinant DNA techniques were per-
formed as described by Sambrook and Russell [25]. 
Restriction endonucleases, SacII, HidIII, NgoMIV, KpnI, 
SspI, were purchased from New England Biolabs (USA) 
and Srf I from Stratagene (USA). For PCR, AccuPrime Pfx 
DNA polymerase (Invitrogen, USA) was used as recom-
mended by the manufacturer. DNA fragments were 
separated and isolated from agarose gels using a MinElute 
kit (Qiagen, Germany).
Extraction of viral RNA and RT-PCR
PK-15 cells were infected with parental LOM virus at a 
multiplicity of infection (MOI) of 1, and the culture 
supernatant was collected at 72 h post-infection (p.i.). The 
culture supernatant was clarified by centrifugation at 1,000 
× g for 10 min; RNA was extracted with an RNeasy Mini 
kit (Qiagen, Germany) according to the manufacturer’s 
recommendations. The viral RNA was resuspended in 
nuclease-free water. cDNA was synthesized using Superscript 
III (Invitrogen, USA) with specific primer sets to generate 
eight individual PCR fragments (designated amplicons 1
∼8, Table 1) according to the manufacturer’s recommen-Infectious cDNA clone of LOM strain    83
Table 1. Primers used for RT-PCR to synthesize eight overlapping cDNA clones for creating Flc-LOM
Primer name Nucleotide sequence
Location within 
LOM genome
Amplicon 1
XT7-KLOM 5´-CTACTCGAGTTAATACGACTCACTATAGTATACGAGGTTAGCTC-3´          1∼17
KLOM-5 5´-GTCTGGCATTCTCTATAGTGTTG-3´   1,735∼1,757
Amplicon 2
KLOM-27 5´-GAATACCCAAGACGGCCTGTACCAC-3´   1,054∼1,078
KLOM-28 5´-GGAACCTGCCACGCAAATGGCCTTA-3´   2,572∼2,596
Amplicon 3
KLOM-29 5´-GTTATTTGAAGAGGCAGGACAGGTC-3´   2,266∼2,290
KLOM-16 5´-CAATGGCAACATGGTACCTGTTATTG-3´   4,440∼4,465
Amplicon 4
KLOM-14 5´-GTACGGATATAGCCATAGCTAC-3´   3,942∼3,963
KLOM-2 5´-GACCGACCTAGGAAGTTCCGTG-3´   5,839∼5,860
Amplicon 5
KLOM-20 5´-CTACAACTCAGGCTACTATTATAG-3´   6,406∼6,429
KLOM-25 5´-GACCAGAGTGGAGTGATCAACCTC-3´   8,852∼8,875
Amplicon 6
KLOM-8 5´-GAAGCAGTGCAGACAGTCGGCAACCCTC-3´   8,240∼8,767
KLOM-18 5´-CAGATTGTCAATAATCTCTTCGAC-3´ 10,634∼10,657
Amplicon 7
KLOM-19 5´-GAGAGGAATAAACAGGAAGGGTG-3´ 10,552∼10,577
KLOM-4 5´-GCTACTCACTAGTCTGTCTGC-3´ 11,858∼11,878
Amplicon 8
KLOM-1 5´-CA ACCACAATCC TGGCTAAAAT GGCCACAAG-3´ 11,469∼11,499
BS-KLOM 5´-TAGGATCCGCCCGGGCCGTTAGGAAATTAC-3´ 12,281∼12,298
dations. PCR was carried out using Pfx DNA polymerase 
(Invitrogen, USA) for higher DNA synthesis fidelity. 
Briefly PCR mixture was made by mixing 5 μL of 10 × Pfx 
DNA polymerase buffer, 1.5 μL of each 10 μM of primer 
mix, 200 ng of template DNA, 2.5 U of Pfx DNA poly-
merase and adjust to 50 μL with autoclaved distilled water. 
Denature the mixture for 2 min at 95
oC and anneal at room 
temperature for 5∼10 min. PCR amplication cycles as 
follows: denaturaton at 95
oC for 15 sec, annealing at 55∼
64
oC for 30 sec and extension at 68
oC for 2∼3 min and a 
single 5 min extension at 68
oC.
Construction of Flc-LOM
To generate a full-length infectious cDNA clone of LOM, 
we used a modified methods previously described by 
Meyer et al. [16]. To assemble a single clone, the eight 
overlapping cDNA amplicons were inserted into a 
pACYC177 plasmid (New England Biolabs, USA), in 
which the kanamycin resistance site completely deleted, 
using available restriction sites in the amplicons along with 
SacII and Srf I sites in the vector (Fig. 1A, left panel). First, 
the 5´ terminal amplicon 1 (1∼1,256 bp) of the viral 
genome was modified so that it included a T7 promoter and 
unique SacII site, derived from pGEM-T Easy (Promega, 
USA), for insertion. The 3´ terminal amplicon 8 (11,729∼
12,298 bp) was inserted into the unique SrfI site to yield the 
authentic viral genome (Fig. 1A, right panel). The modified 
5´ and 3´ end fragments in pACYC177 were digested with 
HindIII and NgoMIV, and subsequently ligated to amplicon 
2 (1,256∼2,440 bp). Using this construct, we continued to 
insert amplicons into the plasmid. For example, amplicon 3 
(2,440∼4,453 bp) was digested with NgoMIV and KpnI, 
and ligated into the restriction site of amplicon 2. Amplicons 
4, 5, and 7 were similarly assembled into the appropriate 
restriction sites. Finally, SspI-digested amplicon 6 (8,833∼
10,612 bp) was ligated into the SspI site, generating the 
full-length cDNA clone pFlc-LOM (Fig. 1A).
In  vitro  synthesis  of  viral  RNA,  transfection  of 
PK-15 cells, and rescue of Flc-LOM 
The full-length cDNA clones of LOM were linearized 
with the restriction endonuclease SrfI, which cut at the 3´ 
end of the viral genome. The template DNA was treated 
with proteinase K (200 μg/mL; Promega, USA) to remove 84    Gil-Soon Park et al.
Fig. 1. Strategies for construction and in vitro growth characterization of Flc-LOM. (A) Circular map of pFlc-LOM showing the relative
positions of the LOM cDNA, ampicillin resistance gene, and P15A origin of replication. Locations of relevant restriction sites and the 
T7 promoter are indicated. The T7 RNA promoter was located immediately upstream of the 5´ end of the genome, and a SrfI site was
at the 3´ end. The genome sequences are underlined. (B) Using the classical swine fever virus-specific monoclonal antibody LOM01,
an indirect immunoperoxidase assay of Flc-LOM was performed in PK-15 cells 3 days after infection with a multiplicity of infection 
(MOI) of 1 (a and b, × 200). The Flc-LOM biotype was determined using the exaltation of Newcastle disease virus method. Serial 
dilutions from 10
1.0 to 10
6.0 of Flc-LOM were added to primary swine testicular cells. After 4 days, the supernatant was removed and 
the cells were infected with Newcastle disease virus (10
4.0 PFU/mL). A cytopathic effect was observed 3 days post-infection  and 
photographed using an inverted microscope (c and d, × 200). (C) Replication kinetics of the Flc-LOM and LOM viruses. PK-15 cells
seeded in T25 flasks were infected at a MOI of 1. The data are from three independent experiments. Virus titers are shown as log10 10
4
median TCID50/mL. ST: swine testicular.
contaminating RNAase A, extracted with phenol/chloroform, 
and precipitated with ethanol. Authentic viral RNA was 
obtained by transcription from the T7 RNA polymerase 
promoter using a T7 MEGAscript kit  (Ambion, USA). 
After TURBO DNase I (Ambion, USA) digestion, the 
transcripts were purified by lithium chloride precipitation 
and quantified spectrophotometrically by spectrophotometer 
(ND - 1000; Nano Drop Technologies, USA). In vitro- 
synthesized RNA (1.5 μg) and lipofectin reagent (Invitrogen, 
USA) were used to transfect 2 × 10
5 PK-15cells which were 
grown in 6-well tissue cultue plates (TPP, Switzerland). 
Culture supernatants were collected 3 days after transfection, 
and 1 mL of culture supernatants were inoculated into the 
monolayers of PK-15 cells to determine the presence of 
infectious virus by immunocytochemical staining [8]. The 
culture supernatants with virus were used for virus passage for 
amplification, determination of replication kinetics, and 
experimental infection of pigs. 
In vitro characterization of Flc-LOM 
The viruses were characterized by an indirect immuno-
peroxidase assay. PK-15 cells were infected with a 10-fold 
dilution of Flc-LOM, and the titer was determined 48 h 
later by immunocytochemical staining the cells with the Infectious cDNA clone of LOM strain    85
monoclonal antibody LOM01 (Jeno Biotech, Korea) 
directed against glycoprotein E2 [8]. The enhancing effect 
of CSFV on Newcastle disease virus (NDV) multiplication 
in primary swine testicular cells, known as exaltation of 
Newcastle disease (END) virus method, was evaluated as 
previously described [14]. Primary swine testicular cells 
were prepared from testicls removed aseptically from a 10 
kg of landlace pig, trypsinized, and 100 μL of 1 × 10
5 cells  
were transferred to each well of 96-well tissue cluture 
plates (TPP, Switzerland). Serial dilutions from 10
򰠏1 to 10
򰠏8 
of Flc-LOM (0.1 mL) were added to each well, and the 
cells were infected for 2 h at 37
oC. The α-EMEM 
(Invitrogen, USA) with 10% FBS(Invitrogen, USA) was 
changed after 72 h, and the plates were inoculated with 
NDV Miyadera strain (10
6 PFU/mL). After 72 h of 
incubation, we observed cytopathic effects. The growth 
kinetics of Flc-LOM and parental LOM were determined 
in PK-15 cells. Subconfluent monolayers in T25 flasks 
(TPP, Switzerland) were infected at an MOI of 1. Cells 
were incubated for 1 h at 37
oC, washed, and then incubated 
in fresh α-EMEM (Invitrogen, USA). At the indicated 
times p.i., the respective cell cultures were frozen to stop 
virus replication, and the virus was titrated in PK-15 cells 
as follow. Serial dilutions from 10
򰠏1 to 10
򰠏8 of Flc-LOM 
(0.1 mL) were added to 96 well tissue culture plate. Add to 
all wells 50 μL of growth media containg 2 × 10
5 cells. 
Titer was determined 48 h later by immunocytochemical 
staining the cells with the monoclonal antibody LOM01(Jeno 
Biotech, Korea) directed against glycoprotein E2 [8].
Animal experiments
Eighteen 45-day-old specific pathogen-free piglets with a 
certified record of the absence of CSFV infection were 
purchased from Optifam Solution (Korea).  The animals 
were divided into three groups: two experimental groups (n  
= seven animals per group) and one control group (n = 4). 
In each of the two experimental groups, five piglets were 
inoculated intramuscularly with parental LOM virus or 
full-length cDNA-derived Flc-LOM. Inoculation dose of 
Flc-LOM and LOM virus was 10
4 median tissue culture- 
infective doses/mL (TCID50/mL) in a volume of 1 mL; two 
piglets in each group were designated as sentinels. The four 
control piglets were inoculated with 1 mL of α-EMEM 
(Invitrogen, USA) with 5% FBS (Invitrogen, USA).  After 
35 days, three piglets in the Flc-LOM and LOM groups and 
four in the control group were challenged with SW03, a 
virulent CSFV strain, at a virus concentration of 100 LD50  
by intramuscular inoculation. During the course of the 
experiment, the piglets were monitored daily for clinical 
signs (coughing, sneezing, appetite loss, and movement) 
and rectal temperature was measured. Blood samples 
along with fecal and nasal swabs were taken for virological 
and serological examination before and after primary 
inoculation and challenge. Blood samples were also used 
to determine leukocyte counts. Twenty-eight days after the 
challenge, the piglets inoculated with Flc-LOM or LOM 
and the control piglets were euthanized. Blood and tissue 
samples from tonsil, spleen, liver, lung, heart, kidney and 
mesenteric lymphonode were collected for virological 
examination. Virus was isolated from blood and tissue 
samples by co-cultivation with PK-15 cells for 4 days. 
After incubation, the cells were analyzed for detection of 
E2 antigen by immunofluorescence assay with the 
monoclonal antibody LOM01 (Jeno Biotech, Korea). To 
detect CSF-specific neutralizing antibodies, a neutralizing 
peroxidase-linked assay was performed according to the 
standards manual of the World Organization for Animal 
Health [8]. Neutralizing antibody titers were expressed as 
reciprocal numbers of the highest two-fold serum dilution. 
Two-fold dilutions of serum starting at 1 : 2 were prepared 
for this experiment. Serum dilutions higher than eight were 
positive.
Results
Sequencing and cloning of the full-length genomic 
RNA of CSFV LOM
The full-length genomic sequence of the CSFV LOM 
strain was determined. Eight overlapping cDNA fragments 
were generated by RT-PCR using various PCR primers 
(Table 1). All regions of the genome were sequenced by at 
least three independent RT-PCR procedures. The genome 
of the virus was determined to be 12,298 nucleotides in 
length. Based on a comparison of the complete nucleotide 
sequence of the CSFV LOM strain with sequences found in 
GenBank, LOM was found to be most closely related (with 
99% nucleotide sequence identity) to the CSFV strain 
Alfort/187 (GenBank No. X87939.1) and Pestivirus type 2 
strain Alfort A19 (GenBank No. U90951.1), a moderately 
virulent strain. The LOM sequence also showed 98% 
identity with the published sequences for the vaccine 
referred to as Thiverval and with GPE
򰠏 strains (GenBank 
Nos. EU490425.1 and D49533.1, respectively).
When each of the eight PCR amplicons, representing 
different regions of the LOM genome, was subcloned and 
sequenced, eight nucleotide alterations were observed 
(Table 2). Two mutations, C to T at nucleotide position 52 
of the genome and A to G at position 96, were in the 
non-translated region. Two mutations, G405A and G6049A, 
resulted in the substitution of glycine for glutamic acid and 
methionine for isoleucine, respectively. The other four 
changes were silent mutations. Nearly all of the amplicons 
deviated from the consensus sequence by at least one base 
substitution, presumably due to PCR-induced mutations; 
however, the resultant amino acid changes had no effect on 
the recovery of infectious clones and thus may serve as 
genetic markers.86    Gil-Soon Park et al.
Table 2. Nucleotide and predicted amino acid differences 
between LOM and Flc-LOM
Nucleotide 
position
Nucleotide 
in LOM*
Nucleotide in 
Flc-LOM
†
Amino acid 
change
Genome 
position
    52 C T NTR
    96 A G NTR
  405 G A G → EN
pro
2608 A G Silent E2
5899 A G Silent NS3
5956 G A Silent NS3
6049 G A M → IN S 3
7054 G T Silent NS4A
*,†Nucelotide positions within the LOM and Flc-LOM genome are 
based on GenBank accession Nos. EU789580 and EU915211, 
respectively.
Construction and recovery of infectious Flc-LOM
To assemble the eight overlapping cDNA fragments into 
a single clone, the amplicons were sequentially ligated into 
the low copy-number plasmid pACYC177 after the 
plasmid was cleaved with the following enzymes: HindIII 
at nucleotide position 1,256; NgoMIV at 2,440; KpnI at 
4,453; BamHI at 6,437; SspI at 8,833 and 10,612; HindIII 
at 11,729; and SrfI at 12,298 (Fig. 1A, left panel). The 5´ 
end of the genome included a SacII restriction site and the 
T7 promoter sequence immediately upstream of the viral 
genome for in vitro transcription of authentic viral RNA. 
At the 3´ end of the viral genome, a SrfI restriction site was 
introduced to allow the generation of authentic viral RNA 
by runoff transcription (Fig. 1A, right panel). The assembled 
full-length cDNA clone, called pFlc-LOM, was linearized 
by digestion with SrfI and used as a template for in vitro 
transcription by T7 RNA polymerase. 
PK-15 cells were transfected with the in vitro transcripts 
by liposome-mediated transfection. About 50% of the cells 
expressed envelope glycoprotein E2 at 72 h post-transfection. 
Supernatants collected from the transfected cells contained 
infectious CSFV as demonstrated by the addition of 
supernatant to PK-15 cells. Culture supernatant from the 
first passage was recovered at 3 days p.i. and consistently 
yielded a viral titer of 10
5.5 TCID50/mL. To confirm that the 
virus was recovered from cells infected with Flc-LOM 
transcripts, we used an immunoperoxidase assay with the 
monoclonal antibody LOM01 raised against glycoprotein 
E2 of CSFV. The cytoplasm-specific staining pattern of 
Flc-LOM-infected cells was identical to that of cells 
infected with the parental LOM virus (Fig. 1B, upper 
panel). Nucleotide sequencing results confirmed that the 
rescued virus maintained the Flc-LOM nucleotide changes 
(Table 2). 
In vitro growth properties of Flc-LOM
Pestiviruses are divided into two biotypes, cytopathogenic 
and non-cytopathogenic, based on the resulting distingui-
shable morphological changes in cultured cells. We tested 
the END phenomenon in swine testicular cell cultures. 
Flc-LOM stimulated NDV cytopathogenicity in primary 
swine testicular cells, indicating that one biological phenotype 
of Flc-LOM was END phenomenon-positive (Fig. 1B, 
lower panel). An analysis of the replication kinetics of 
Flc-LOM and parental LOM virus in PK-15 cells revealed 
that the LOM virus grew faster and reached a higher titer 
(by about 1 log unit) than the Flc-LOM virus at different 
time points (Fig. 1C). 
In vivo properties of Flc-LOM in pigs
After immunizing pigs with the Flc-LOM or parental 
LOM virus, the general condition of the animals was 
normal, irrespective of the inoculum, and no clinical signs, 
leukopenia, or fever were observed. Blood leukocytes 
from all vaccinated animals were positive for the virus, as 
determined by RT-PCR, 5∼7 days after immunization. In 
several immunized piglets, viral antigens were detected by 
RT-PCR in fecal and nasal swabs 5∼7 days p.i. (Table 3). 
None of the sentinel animals in the immunized groups 
showed increased body temperature or leukopenia, and no 
viral antigen was detected in their blood, fecal, or nasal 
swabs. RT-PCR was used to identify viral antigens in tissue 
samples after immunization and challenge (Table 4). After 
immunization or challenge, viral antigens were detected 
from tonsil, lung, spleen, liver, and mesenteric lymph node 
of pigs in LOM group, but only from the tonsil in Flc-LOM 
group was detected. However, viral antigens from all tissue 
samples in control group were detected. Serological 
screening using a LOM-specific neutralization assay demon-
strated that none of the Flc-LOM or LOM sentinel animals 
had seroconverted (data not shown). Although Flc-LOM 
viremia was detected at an early stage, shedding of the 
virus was not observed in the sentinel animals. On day 28 
p.i., the animals immunized with Flc-LOM and LOM 
strains had CSF-neutralizing antibody titers higher than 8, 
whereas none of the non-immunized animals had 
CSFV-E2- or LOM-specific serum antibodies (Table 5).
After intramuscular challenge with the virulent CSFV 
strain SW03 at 35 days after immunization, the health of 
the pigs previously inoculated with Flc-LOM or LOM 
remained completely unchanged, and neither fever nor 
leukopenia was detected in any of the animals (Fig. 2). In 
contrast, all the control pigs became anorectic and severely 
depressed after CSFV SW03 inoculation. Typical CSF 
symptoms started 3 days after inoculation and lasted for 14
∼21 days. Severe leukopenia occurred between days 3 
and 21 post-challenge, and fever with body temperatures 
higher than 41.5
oC lasted for several days in the control 
pigs (Fig. 2). These results indicate that, like the pigsInfectious cDNA clone of LOM strain    87
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Fig. 2. Evaluation of clinical responses in pigs infected with 
Flc-LOM or LOM. CSFV-specific immunity was determined on
day 35 p.i. with the virulent CSFV strain SW03. (A) Peripheral 
white blood cell (WBC) counts in pigs infected with Flc-LOM or
LOM. Mean values of the leukocyte counts of the Flc-LOM (n =
5), LOM (n = 5), and control groups (n = 5) are shown. Standard
deviations are expressed as error bars (B). Body temperatures 
were recorded for the Flc-LOM, LOM, and non-vaccinated 
control groups until 2 weeks after challenge.
Table 5. Mean neutralizing antibody titers (log2) in pigs from the Flc-LOM, LOM, and control groups after immunization or challenge 
infection
Group
Days after 1st immunization (days after 2nd immunization)
Days after challenge infection
71 4 2 1
0 7 14 21 28 (7) 35 (14) 42 49 56
Flc-LOM
LOM
Control
0.0
0.0
0.0
0.8
0.8
0.0
5.8
5.3
0.0
7.0
6.3
0.0
8.3
8.0
0.0
8.5
8.8
0.0
10.3
10.0
0.0
11.0
11.0
0.0
12.0
12.0
2.0
immunized with parental LOM, the Flc-LOM-immunized 
pigs were completely protected against challenge with the 
virulent SW03 strain. Overall, the infectious Flc-LOM 
virus cloned from the LOM strain of CSFV retained the 
biological and immunogenic properties of the parental 
virus.
Discussion
Here, we described the construction of an infectious 
cDNA clone of the CSFV LOM strain. Its biological 
characteristics were evaluated based on in vitro growth 
properties and the resulting END phenomenon in primary 
ST cells. We also demonstrated the utility of Flc-LOM as a 
vaccine candidate by investigating the in vivo phenotype 
and immunogenicity of this construct in a pig model. This 
study is the first to perform the construction of a full-length 
LOM strain. This clone will prove valuable for studying 
the replication, virulence, cell and host tropism, and 
pathogenesis of CSFV.
Reverse genetics is a useful tool for studying viral 
replication, pathogenesis, and the in vivo function of 
individual viral proteins as well as developing viruses as 
vectors and vaccines. Reverse genetics allows the intro-
duction of changes at specific sites or regions of the viral 
genome to create modified infectious viruses [15]. This 
technology is particularly useful for RNA viruses because 
their genomes are unstable. The construction of infectious 
cDNA clones of several CSFV strains has been previously 
reported  [22]. 
In Korea, an attenuated live vaccine (LOM strain) has 
been used extensively since 1974 to control CSF in the 
field. Recently, some pig farmers and veterinarians have 
suspected that the strain may have mutated and became 
pathogenic [13]. The LOM strain has been maintained 
through a number of passages in bovine/porcine kidney 
cells for several years. Although this strain is considered 
genetically stable, its reversion to a virulent strain seems be 
possible. For this reason, we established Flc-LOM to 
analysis the pathogenesis of the LOM strain. The LOM 
strain is an effective and safe live vaccine. However, pigs 
that are vaccinated with the LOM strain cannot be 
serologically differentiated from pigs which have been Infectious cDNA clone of LOM strain    89
infected with a CSFV field strain. The Flc-LOM clone 
created in our study will provide the basis for constructing 
chimeric viruses and marker vaccine.
To establish authentic cDNA clones of the LOM strain, 
the full-length genomic RNA sequence was determined. 
To ensure the authenticity of the synthesized RNA, the 
clone sequence (Flc-LOM) was placed downstream of a T7 
promoter, and a SrfI site was introduced at its 3´ end. 
Full-length genomic RNA was synthesized in vitro, and the 
RNA transcripts were used for transfection. The expre-
ssion of E2 proteins appeared as early as 2 days post- 
transfection and infectious Flc-LOM virus was readily 
recovered. The recovered Flc-LOM virus was stable for 
several passages with a titer of >10
5.5 TCID50/mL (data not 
shown). The titer of Flc-LOM in PK-15 cells was reduced 
by only about 1 log unit compared to that of the parental 
LOM strain. We speculate that amino acid or nucleotide 
differences between the Flc-LOM and parental virus were 
probably responsible for inefficient Flc-LOM growth in 
PK-15 cells. Establishment of a pathogenic infectious 
cDNA clone will benefit investigations of certain genes 
associated with the pathogenesis and virulence of CSFV.
The END phenomenon is based on the enhancing effect 
of CSFV on NDV in swine testicular cells [14], which is 
one CSFV characteristic. Sato et al. [26] previously 
reported that LOM strains was not detected by the 
cytopathic effect in the END test. But it was reported that 
LOM vaccine used in Korea was mixed with two types of 
viruses showing END phenomenon-negative or END 
phenomenon-positive [3]. Others also reported that low- 
virulence strains of hepatitis C virus in Germany could not 
be detected by the END method [20]. Most CSFV field 
isolates that show the END phenomenon do not induce a 
cytopathic effect in porcine cell cultures [14]. The Japanese 
live vaccine GPE
򰠏 strains prepared by long-term serial 
passage are END phenomenon-negative. To date, there 
have been no reports of END phenomenon-negative 
viruses being isolated independently from animals suffering 
from CSF in field outbreaks [1]. 
Although Flc-LOM was shown to be non-cytopathogenic 
but END phenomenon-positive, the efficacy and safety of 
Flc-LOM as a vaccine candidate were demonstrated. These 
results implied that there is no direct relationship between 
the virulence of CSFV and the END phenomenon. This 
suggests that our Flc-LOM strain was selected as END 
phenomenon-positive strain in contrast to the LOM strain 
of Sakoda et al. [24] which is END phenomenon-negative. 
Difference in the presence of the END phenomenon might 
have occurred because the LOM strain of Sato et al. [26] is 
an earlier isolate and may contain a heterogeneous 
population with END phenomenon-negative virus or END 
phenomenon-positive virus. Further investigation is 
necessary to determine the phenotype of END phenomenon- 
negative virus  and genetical characterization of this virus.
To date, all live and modified live vaccine candidates 
[4,27,32] that express CSFV structural proteins need to be 
delivered in multiple or at very high doses to induce 
clinical protection. In our animal experiments, the newly 
established live vaccine Flc-LOM provided complete 
protection from virulent CSFV challenge after only a single 
application. Flc-LOM-infected animals did not develop a 
fever and maintained body temperatures at pre-challenge 
levels. In contrast, the control pigs had severe forms of the 
disease and had to be euthanized. Leukocyte counts in 
Flc-LOM-infected pigs remained stable. Although shed 
Flc-LOM virus was undetectable in nasal and fecal swabs, 
some virus was detected in blood samples. The detection of 
viral genomes has been described to be more sensitive than 
conventional virus isolation, especially in the presence of 
neutralizing antibodies [10]. Nevertheless, amplification 
of the Flc-LOM genome in nasal and fecal swabs was not 
successful. The detection of viral antigen by RT-PCR 
suggested that Flc-LOM was attenuated to a greater extent 
than parental LOM virus in terms of in vivo replication 
efficacy. Non-vaccinated sentinel animals did not seroconvert 
against Flc-LOM or exhibit signs of disease. Therefore, we 
speculate that Flc-LOM is highly effective in reducing or 
preventing transmission of CSF virus in the field. A major 
safety aspect concerning vertical transmission in pregnant 
sows is currently under investigation.
Flc-LOM, the infectious clone of CSFV LOM, proved to 
be as avirulent as the parental LOM strain. This clone did 
not cause any disease symptoms, but induced a distinct 
antibody response and provided complete protection from 
challenge with the virulent strain SW03. Similarly, de Smit 
et al. [5] have reported a cDNA clone derived from the C 
strain, which is the most widely used vaccine, that also 
retains its parental phenotypic characteristics, including 
antigenic and immunogenic properties. Production of a 
rationally designed live attenuated vaccine will be valuable 
for disease control strategies in the event of a future CSFV 
outbreak.
In conclusion, we created Flc-LOM from an infectious 
cDNA clone of an attenuated CSFV vaccine strain and 
compared its biological properties with those of the 
parental LOM vaccine strain. Flc-LOM possessed all the 
biological and avirulent properties of its parental strain in 
vitro and in vivo. This clone will provide an opportunity for 
genetic manipulation of the LOM virus, including the 
creation of marker vaccines, and will be useful for 
identifying the genetic and serological determinants of 
CSFV virulence.
Acknowledgments 
This study was funded by the Animal, Plant and Fisheries 
Quarantine and Inspection Agency, Ministry for Food, 
Agriculture, Forestry and Fisheries, Korea (B-AD14- 90    Gil-Soon Park et al.
2009-11-02). 
References
1. Aoki H, Sakoda Y, Nakamura S, Suzuki S, Fukusho A. 
Cytopathogenicity of classical swine fever viruses that do 
not  show  the  exaltation  of  Newcastle  disease  virus  is 
associated with accumulation of NS3 in serum-free cultured 
cell lines. J Vet Med Sci 2004, 66, 161-167.
2. Cha SH, Choi EJ, Park JH, Yoon SR, Kwon JH, Yoon 
KJ,  Song  JY.  Phylogenetic  characterization  of  classical 
swine fever viruses isolated in Korea between 1988 and 
2003. Virus Res 2007, 126, 256-261.
3. Choi CH, Lee OS, Kim YH, An SH, Hwang EK. Studies 
on the development of hog cholera live vaccine 1. cloning 
and identification of a new attenuated hog cholera virus. Res 
Rept Rural Dev Admin 1988, 30, 42-48.
4. de Smit AJ, Bouma A, van Gennip HGP, de Kluijver EP, 
Moormann  RJM.  Chimeric  (marker)  C-strain  viruses 
induce clinical protection against virulent classical swine 
fever  virus  (CSFV)  and  reduce  transmission  of  CSFV 
between vaccinated pigs. Vaccine 2001, 19, 1467-1476.
5. de Smit AJ, van Gennip HGP, Miedema GKW, van Rijn 
PA, Terpstra C, Moormann RJM. Recombinant classical 
swine fever (CSF) viruses derived from the Chinese vaccine 
strain  (C-strain)  of  CSF  virus  retain  their  avirulent  and 
immunogenic characteristics. Vaccine 2000, 18, 2351-2358.
6. D e  V o s  C J ,  S a a t k a m p  H W ,  H u i r n e  R B .  Cost- 
effectiveness of measures to prevent classical swine fever 
introduction into The Netherlands. Prev Vet Med 2005, 70, 
235-256. 
7. Dong  XN,  Chen  YH.  Marker  vaccine  strategies  and 
candidate CSFV marker vaccines. Vaccine 2007, 25, 205- 
230.
8. Drew  T.  Classical  swine  fever  (hog  cholera).  In:  Office 
International  des  Epizooties  (OIE)  (ed.).  Manual  of  Dia-
gnostic Tests and Vaccines for Terrestrial Animals: Mammals, 
Birds and Bees. 6th ed. pp. 1092-1106, OIE, Paris, 2008.
9. Genghini  R,  Tiranti  I,  Wittouck  P.  Pig  chromosome 
aberrations after vaccination against classical swine fever in 
field trials. Vaccine 2002, 20, 2873-2877.
10. Haegeman A, Dewulf J, Vrancken R, Tignon M, Ribbens 
S, Koenen F. Characterisation of the discrepancy between 
PCR and virus isolation in relation to classical swine fever 
virus detection. J Virol Methods 2006, 136, 44-50.
11. Kang BJ, Kwon HJ, Kim SJ, Mun JB. A field application 
of tissue culture attenuated hog cholera (LOM) vaccine. Res 
Rept Rural Dev Admin 1971, 17, 27-33.
12. Kang  BJ.  Studies  on  low  virulent  hog  cholera  virus 
(LOM-E+) . Doctoral thesis, Azabu University Japan 1971.
13. Kim B, Song JY, Tark DS, Lim SI, Choi EJ, Kim J, Park 
CK, Lee BY, Wee SH, Bae YC, Lee OS, Kwon JH, Kang 
WC,  Kim  TY,  Kim  JH,  Lee  JH,  Kang  MI.  Feed 
contaminated with classical swine fever vaccine virus (LOM 
strain) can induce antibodies to the virus in pigs. Vet Rec 
2008, 162, 12-17.
14. Kumagai T, Shimizu T, Matumoto M. Detection of hog 
cholera virus by its effect on Newcastle disease virus in 
swine tissue culture. Science 1958, 128, 366.
15. Lee C, Calvert JG, Welch SKW, Yoo D. A DNA-launched 
reverse  genetics  system  for  porcine  reproductive  and 
respiratory syndrome virus reveals that homodimerization of 
the nucleocapsid protein is essential for virus infectivity. 
Virology 2005, 331, 47-62.
16. Mayer  D,  Thayer  TM,  Hofmann  MA,  Tratschin  JD. 
Establishment and characterisation of two cDNA-derived 
strains of classical swine fever virus, one highly virulent and 
one avirulent. Virus Res 2003, 98, 105-116.
17. Meyers G, Thiel HJ, Rümenapf T. Molecular cloning and 
nucleotide sequence of the genome of hog cholera virus. 
Virology 1989, 171, 555-567.
18. Meyers  G,  Rümenapf  T.  Classical  swine  fever  virus: 
recovery of infectious viruses from cDNA constructs and 
generation of recombinant cytopathogenic defective interfering 
particles. J Virol 1996, 70, 1588-1595.
19. Moormann RJM, van Gennip HGP, Miedema GKW, 
Hulst MM, van Rijn PA. Infectious RNA transcribed from 
an engineered full-length cDNA template of the genome of a 
pestivirus. J Virol 1996, 70, 763-770.
20. Nishimura Y, Sato U, Hanaki T, Nobuto K. Studies on the 
tissue culture of hog cholera virus. II. Neutralization test by 
means of the influence of hog cholera virus infection on 
newcastle disease virus infection (HEIC method). Nihon 
Juigaku Zasshi 1964, 26, 133-140.
21. Risatti GR, Borca MV, Kutish GF, Lu Z, Holinka LG, 
French RA, Tulman ER, Rock DL. The E2 glycoprotein of 
classical swine fever virus is a virulence determinant in 
swine. J Virol 2005, 79, 3787-3796.
22. Ruggli N, Tratschin JD, Mittelholzer C, Hofmann MA. 
Nucleotide sequence of classical swine fever virus strain 
Alfort/187 and transcription of infectious RNA from stably 
cloned full-length cDNA. J Virol 1996, 70, 3478-3487.
23. Rümenapf T, Unger G, Strauss JH, Thiel HJ. Processing 
of the envelope glycoproteins of pestiviruses. J Virol 1993, 
67, 3288-3294.
24. Sakoda Y, Ozawa S, Damrongwatanapokin S, Sato M, 
Ishikawa K, Fukusho A. Genetic heterogeneity of porcine 
and  ruminant  pestiviruses  mainly  isolated  in  Japan.  Vet 
Microbiol 1999, 65, 75-86.
25. Sambrook J, Russell DW. Molecular Cloning. 3rd ed. pp. 
1.31-1.162,  Cold  Spring  Harbor  Laboratory  Press,  New 
York, 2001.
26. Sato  U,  Hanaki  T,  Nobuto  K.  Attenuation  of  the  hog 
cholera virus by continuous cell-virus propagation. 3. Growth 
interference of Newcastle disease virus by attenuated hog 
cholera virus and its application to virus titration and the 
neutralization  test.  Arch  Gesamte  Virusforsch  1969,  26, 
1-10.
27. van  Gennip  HGP,  Bouma  A,  van  Rijn  PA,  Widjojo-
atmodjo  MN,  Moormann  RJM.  Experimental  non- 
transmissible  marker  vaccines  for  classical  swine  fever 
(CSF) by trans-complementation of E
rns or E2 of CSFV. 
Vaccine 2002, 20, 1544-1556.
28. van Oirschot JT. Vaccinology of classical swine fever: 
from lab to field. Vet Microbiol 2003, 96, 367-384.
29. van  Regenmortel  MHV,  Fauquet  CM,  Bishop  DHL, 
Carsten EB, Estes MK, Lemon SM, Maniloff J, Mayo 
MA,  McGeoch  DJ,  Pringle  CR,  Wickner  RB.  Virus Infectious cDNA clone of LOM strain    91
Taxonomy. 1st ed. pp. 867-872, Academic Press, San Diego, 
2000.
30. Vassilev VB, Collett MS, Donis RO. Authentic and chimeric 
full-length genomic cDNA clones of bovine viral diarrhea 
virus  that  yield  infectious  transcripts.  J  Virol  1997,  71, 
471-478.
31. Wee SH, Park CK, Jeong JM, Kim CH, Hwang IJ, Kim 
SJ, Yoon H, Lee ES, Nam HM, Park JY, Moon OK. 
Outbreaks of classical swine fever in the Republic of Korea 
in 2003. Vet Rec 2005, 157, 113-115.
32. Widjojoatmodjo MN, van Gennip HGP, Bouma A, van 
Rijn PA, Moormann RJM. Classical swine fever virus E
rns 
deletion mutants: trans-complementation and potential use 
as  nontransmissible,  modified,  live-attenuated  marker 
vaccines. J Virol 2000, 74, 2973-2980.
33. Xu J, Mendez E, Caron PR, Lin C, Murcko MA, Collett 
MS,  Rice  CM.  Bovine  viral  diarrhea  virus  NS3  serine 
proteinase: polyprotein cleavage sites, cofactor requirements, 
and molecular model of an enzyme essential for pestivirus 
replication. J Virol 1997, 71, 5312-5322.